Nov 12, 2018
Just what the doctor ordered - CURE biotech ETF now available (ASX code: CURE) • CURE is Australia’s only pure-play biotech ETF • Provides access to a range of companies including the world’s leading producer of orphan drugs and another with more than US$5 billion in sales for its rheumatoid arthritis treatment • CURE is the latest in the ‘Future Present’ ETF range designed to deliver outsized returns SYDNEY, November 12 – ETF Securities has launched its CURE exchange traded fund (ETF) on the ASX, providing Australian investors with broad-based exposure to some of the world’s most exciting healthcare biotechnology companies. CURE physically replicates the S&P Biotechnology Select Industry Index, which has achieved annual growth of 21.9 percent in Australian dollar terms over the five years to 31 October 2018 compared with annual gains of 6 percent by the local benchmark S&P/ASX 200 index over the same period. “The index tracks many of the US healthcare biotechnology enterprises that are developing the intellectual property for the breakthroughs of the future,” said Kris Walesby, Head of ETF Securities Australia, the country’s only independent and locally-owned ETF provider. “The Australian equities market simply cannot provide a comparable universe of investible stocks by either size or variety,” said Mr Walesby. “In fact, there are probably only two listed Aussie companies that could make it into the US index if they were listed there.” “If you want broad-based biotech exposure, you have to go to the US market,” Mr Walesby added. With a fee of 0.45 per cent, CURE offers investors exposure to more than 120 biotechnology firms, concentrated on small and mid-cap companies. There are demanding filters to be met before a company can be included in CURE, with companies needing to meet S&P Dow Jones Indices’ Float Adjustment liquidity requirements. Stocks are modified equally weighted and no stock can have a weighting of more than 4.5 per cent. Among the stocks underpinning the index is Celgene, which is the world’s largest orphan drug manufacturer. This company has a focus on developing therapies for a number of rare and difficult to treat cancers. Celgene had worldwide orphan drug sales in 2017 of US$10 billion. Investors in CURE will also gain access to biotech major Amgen, whose Enbrel treatment for rheumatoid arthritis and related conditions had 2017 sales of US$5.4 billion. Its market cap sits at around US$130 billion. “This is the first time an Australian investor can obtain a pure-play exposure to biotechnology developers in the US healthcare industry while also retaining all the protections that diversification brings,” Mr Walesby said. “This is very much a high growth-oriented product,” he said. “Given the mainly mid- and small-cap profiles of the constituent stocks, we’d expect to see profitable M&A activity. We are pleased to be adding CURE to our ‘Future Present’ series of ETFs.” Founded by Australian philanthropist Graham Tuckwell, ETF Securities created the first commodity exchange traded product with a gold ETF and now has more than $1 billion in funds under management in Australia.
Oct 23, 2018
Pursuant to Part 7.9 of the Corporations Act, attached is the exposure draft for the ETFS Management (AUS) Limited product disclosure statement. Exposure Draft Product Disclosure Statement - Equity ETFs
Oct 11, 2018
ETFS Management (AUS) Limited ACN 150 433 828 (ETFS), as responsible entity for the ETFS S&P/ASX 100 ETF (ZOZI), has resolved to terminate the Fund (Termination), effective after the close of trading on 31 October 2018 (Last Trading Day). As a result of the Termination, Units in the Fund will be suspended from quotation on the AQUA market of the Australian Securities Exchange (ASX) and removed from trading status after the close of trading on the Last Trading Day and wound up in accordance with Part 5C.9 of the Corporations Act and the Fund's constitution. Background ETFS has undertaken a review of the Fund and determined that it would be in the best interests of Holders to terminate the Fund. ETFS made this determination for several reasons, including that: the Fund has not reached sufficient size to be cost effective for investors relative to other Australian equity ETFs. Management Costs are 0.24% per annum, as detailed in the Product Disclosure Statement (PDS), which are higher than those on offer by comparable Australian equity ETFs with more assets under management. Current asset value is approximately $10 million, and it is not expected that the size of the Fund will increase in the near future, and due to limited secondary market trading in the Fund average bid-offer spreads are higher than for comparable Australian equity ETFs. ETFS has decided to provide Holders with 15 trading days’ notice of its intention to terminate the Fund. This communication outlines the steps that will be taken to affect the Termination of the Fund and seeks to inform you as to what action you may take. Important dates Set out below are a summary of the key dates relating to the Termination. Dispatch of this letter 11 October 2018 Last day for dealings in the Units in the Fund and last day for redemption of Units in the Fund by Authorised Participants (the Last Trading Day) 31 October 2018 The date at which termination will commence (Termination Commencement Date) 31 October 2018 Ex-date for distribution of income for the period 1 October 2018 to 1 November 2018 1 November 2018 The date at which an investor needs to be recorded as the beneficial owner of Units in the Fund in the Clearing House Electronic Subregister System (CHESS) (the Termination Record Date). 2 November 2018 Final distribution to be paid to investors holding Units on the Termination Record Date (the Termination Payment Date). 7 November 2018 The dates above are subject to change. Any change will be announced to the market via the ASX. How will the termination of the Fund affect your Units? As a Holder of Units, you have several choices as to the action you can take in response to this communication. In any event your Units will not be able to be traded on the ASX after the Last Trading Day. You should consult your financial adviser to ensure that you understand the implications, including the costs and risks, of your choice. As a Holder of Units, you may either; sell your Units on the ASX in the ordinary way via your broker prior to the close of trading on the Last Trading Day. ETFS expects that the market makers will continue to make a market for Units until 31 October 2018, redeem your Units with the Issuer in the ordinary way, if you are an Authorised Participant, prior to the close of trading on the Last Trading Day, or hold your Units until the Termination of the Fund and receive a pro-rata share of the proceeds of winding up. If you choose to sell your Units on the ASX, you will incur brokerage costs and any spread costs as you normally would when transacting on the ASX. Similarly, if you are an Authorised Participant and choose to redeem your Units with the Issuer, you will incur the costs associated with a redemption as set out in section 6.4 of the PDS for the Fund. Holders deciding to sell their Units are able to have regard to the prevailing price of the underlying securities and their Units at the relevant time. Performance information for both the Fund and the benchmark Index, as well as the full portfolio holdings of the Fund are published daily on www.etfsecurities.com.au. Where you hold your Units until Termination, you will receive a distribution of income for the period from 29 September 2018 to 1 November 2018, together with an amount in Australian dollars equal to the net asset value per Unit of the Fund on the day the assets of the Fund are sold (which is expected to be the Last Trading Day), multiplied by the number of Units you hold. ETFS will bear all transaction costs associated with the liquidation of the assets of the Fund. Holders should be aware that the price of the underlying securities may change and the net asset value per Unit of the Fund may change between the date of this communication and the completion of Termination. For further information in relation to the Fund or how to sell or redeem your Units, please refer to the PDS. A copy of the PDS is available here.
Sep 28, 2018
Please find the annual financial reports of ETFS Physical Renminbi ETF (ZCNH) which was closed on 6 August 2018 and ETFS Physical Singapore Gold ETF (ZGOL), which was terminated on on 22 June 2018 as below :- ETFS Physical Singapore Gold ETF (ZGOL) annual financial report - 30 June 2018 ETFS Physical Renminbi ETF (ZCNH) annual financial report - 30 June 2018 For any queries, please free feel to contact us by infoAU@etfsecurities.com.au
Sep 19, 2018
This Replacement Product Disclosure Statement (“RPDS”) is dated 19 September 2018 and has been prepared by ETFS Management (AUS) Limited ACN 150 433 828 AFSL number 466778 (“ETFS”) or (the “Responsible Entity”) who is responsible for its content. This RPDS replaces the Product Disclosure Statement dated 5 September 2018. This RPDS sets out information and is an offer document for each of the ETFS S&P/ASX 100 ETF, the ETFS S&P/ ASX 300 High Yield Plus ETF, the ETFS S&P 500 High Yield Low Volatility ETF, the ETFS EURO STOXX 50® ETF, the ETFS Morningstar Global Technology ETF, the ETFS Global Core Infrastructure ETF, the ETFS ROBO Global Robotics and Automation ETF and the ETFS Battery Tech & Lithium ETF (each a “Fund” and together the “Funds”). Each of the Funds is a registered managed investment scheme and a copy of this RPDS has been filed with the Australian Securities and Investments Commission (“ASIC”). To download the RPDS, please click here.
Sep 03, 2018
ACDC ETF captures the structural global shift in the use of energy and dramatic advances in battery technology ACDC adds to the ‘Future Present’ ETF range that includes the outperforming TECH ETF which has gained 40% in a year as well as ROBO SYDNEY, September 3 – ETF Securities today launched an exchange traded fund (ETF) that provides Australian investors with access to companies directly involved in the global energy revolution. Listed today on the Australian Securities Exchanges with the code ACDC, the ETFS Battery Technology and Lithium ETF tracks the performance of battery technology stocks and four lithium producers. “Energy storage is undergoing a massive transformation in Australia and the rest of the world, with lithium considered to be one of the lightest and most efficient technologies,” said Kris Walesby, Head of ETF Securities Australia, which is the nation’s only locally-owned and independent ETF provider. “Battery technology has advanced dramatically and is causing a structural shift in our use of energy both in terms of storage as well as the drive towards cleaner and more efficient energy,” Mr Walesby said, noting the global market for advanced battery materials is expected to increase 50 percent to about US$33 billion in the next four years. Lithium batteries are the mainstay of laptops, smart phones and tablets with their capacity to provide reliable power over a long period of time. Significantly, these batteries also hold the key to delivering electric cars with a longer driving range, with demand expected to surge as the motoring public buy more of these cars. “With a fee of 0.69 per cent, the ACDC ETF provides investors with exposure to 28 stocks from five sectors that include lithium producers such as Australia’s Orocobre, battery producer Samsung SDI, electric vehicle pioneer and battery producer Tesla and industrial specialist Toshiba,” said Mr Walesby. “Using technology to help store more energy in batteries is still in its infancy so companies included in the ACDC ETF and involved with this research must show they have been recommended by the US Department of Energy,’’ Mr Walesby said. In addition to lithium, the ACDC ETF will include exposure to lead, nickel, sodium and zinc batteries and its basket of stocks will be reassessed as other battery technologies such as hydrogen emerge over the longer term. The ACDC ETF is benchmarked against the Solactive Battery Value-Chain Index, created by German index provider Solactive, that has delivered an annual return of 15 per cent per annum over the past five years. “While the humble battery hasn't changed that much in years, we're on the cusp of a power revolution. Some notable as well as some less known but highly focussed companies are working hard to make their mark early with many investors keen to get on board when they can,’’ Mr Walesby said. The ACDC ETF is the latest member of the Future Present range of ETFs that includes the first exchange traded fund in Australia, ROBO, that gives investors access to global companies focusing on robotics, automation and enabling technologies. It now has $125 million under management after less than 12 months of trading while the TECH ETF, another in the Future Present range, allows Australian investors to buy into the growth potential of the world’s top technology stocks including Apple, Google and Microsoft, currently at $74m in FUM. TECH has returned 40 per cent over the past year and focuses on undervalued, high-quality technology businesses that have the potential to maintain a sustainable competitive advantage over the long term. ‘’The idea behind the Future Present program is that it allows investors to get involved with these megatrends that will change the way we live and offer potentially high growth investment opportunities,’’ said Mr Walesby. Founded by Australian philanthropist Graham Tuckwell, ETF Securities created the first commodity exchange traded product with a gold ETF and now has more than $1 billion funds under management in Australia. To download this press release, please click here. For media enquiries contact: Phil Baker P&L Corporate Communications Phone: +61 2 9231 5411 Mobile: +61 416 188 972 Mobile: +61 416 188 972 Email: email@example.com Kris Walesby CEO - ETF Securities Australia Phone: +61 2 8311 3477 Email: firstname.lastname@example.org